Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation

被引:538
作者
Collins, Peter W. [1 ]
Hirsch, Sybil
Baglin, Trevor P.
Dolan, Gerard
Hanley, John
Makris, Michael
Keeling, David M.
Liesner, Ri
Brown, Simon A.
Hay, Charles R. M.
机构
[1] Univ Wales Hosp, Dept Haematol, Cardiff CF14 4XN, Wales
[2] Cardiff Univ, Sch Med, Cardiff, Wales
[3] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England
[4] Addenbrookes Hosp, Cambridge, England
[5] Queens Med Ctr, Nottingham NG7 2UH, England
[6] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[7] Oxford Haemophilia Ctr, Oxford, England
[8] Great Ormond St Hosp Sick Children, London WC1N 3JH, England
[9] Royal Free Hosp, London NW3 2QG, England
关键词
D O I
10.1182/blood-2006-06-029850
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acquired hemophilia A is a severe bleeding disorder caused by an autoantibody to factor VIII. Previous reports have focused on referral center patients and it is unclear whether these findings are generally applicable. To improve understanding of the disease, a 2-year observational study was established to identify and characterize the presenting features and outcome of all patients with acquired hemophilia A in the United Kingdom. This allowed a consecutive cohort of patients, unbiased by referral or reporting practice, to be studied. A total of 172 patients with a median age of 78 years were identified, an incidence of 1.48/million/y. The cohort was significantly older than previously reported series, but bleeding manifestations and underlying diseases were similar. Bleeding was the cause of death in 9% of the cohort and remained a risk until the inhibitor had been eradicated. There was no difference in inhibitor eradication or mortality between patients treated with steroids alone and a combination of steroids and cytotoxic agents. Relapse of the inhibitor was observed in 20% of the patients who had attained first complete remission. The data provide the most complete description of acquired hemophilia A available and are applicable to patients presenting to all centers.
引用
收藏
页码:1870 / 1877
页数:8
相关论文
共 35 条
[21]   Prednisone and low-dose activated prothrombin complex concentrates for FVIII inhibitor in nonhaemophilic patients [J].
Ji, LX ;
Yang, RC ;
Yang, DG ;
Chen, ZK ;
Xing, SH ;
Tian, MG ;
Sun, Y .
HAEMOPHILIA, 1998, 4 (05) :721-724
[22]   Aquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone [J].
Lian, ECY ;
Villar, MJ ;
Noy, LI ;
Ruiz-Dayao, Z .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 69 (04) :294-295
[23]   ACQUIRED HEMOPHILIA - A NATURAL-HISTORY STUDY OF 16 PATIENTS WITH FACTOR-VIII INHIBITORS RECEIVING LITTLE OR NO THERAPY [J].
LOTTENBERG, R ;
KENTRO, TB ;
KITCHENS, CS .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (06) :1077-1081
[24]   Acquired anti-FVIII inhibitors in children [J].
Moraca, RJ ;
Ragni, MV .
HAEMOPHILIA, 2002, 8 (01) :28-32
[25]   ACQUIRED HEMOPHILIA AND ITS MANAGEMENT [J].
MORRISON, AE ;
LUDLAM, CA .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) :231-236
[26]  
MORRISON AE, 1993, BLOOD, V81, P1513
[27]   Treatment of acquired haemophilia with factor eight inhibitor bypassing activity [J].
Sallah, S .
HAEMOPHILIA, 2004, 10 (02) :169-173
[28]  
Sallah S, 2001, CANCER-AM CANCER SOC, V91, P1067, DOI 10.1002/1097-0142(20010315)91:6<1067::AID-CNCR1101>3.0.CO
[29]  
2-4
[30]  
Saxena R, 2000, HAEMOPHILIA, V6, P78